Biorestorative Therapies earnings were -$9.0M for the trailing 12 months ending Dec 31, 2024, with N/A growth year over year. The latest BRTX earnings report on Dec 31, 2024 announced Q4 2024 earnings of -$1.6M, up 49.9% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BRTX reported annual earnings of -$9.0M, with -13.8% growth. The next BRTX earnings date is May 12, 2025.
Biorestorative Therapies Earnings Reports & History FAQ
What were Biorestorative Therapies's earnings last quarter?
On BRTX's earnings call on Invalid Date, Biorestorative Therapies (NASDAQ: BRTX) reported Q4 2024 earnings per share (EPS) of -$0.20, up 57.45% year over year. Total BRTX earnings for the quarter were -$1.64 million. In the same quarter last year, Biorestorative Therapies's earnings per share (EPS) was -$0.47.
When does Biorestorative Therapies report earnings?
The next BRTX earnings date is Invalid Date. Add BRTX to your watchlist to be reminded of Biorestorative Therapies's next earnings date.
Is Biorestorative Therapies profitable or losing money?
As of the last Biorestorative Therapies earnings report, Biorestorative Therapies is currently losing money. Biorestorative Therapies's net profit (also called net income) for the twelve months ending Dec 31, 2024 was -$8.98 million, a 13.81% decrease year over year.
What was BRTX's earnings growth in the past year?
As of Biorestorative Therapies's earnings date in Invalid Date, Biorestorative Therapies's earnings has grown year over year. BRTX earnings in the past year totalled -$8.98 million.
What are Biorestorative Therapies's earnings expectations?
The current EPS estimate for Biorestorative Therapies's earnings report in Invalid Date is -$0.34.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.